Radiopharm Theranostics (NASDAQ:RADX) announced interim findings from its Phase 2b clinical trial evaluating RAD 101, an ...

RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint)First five ...

Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company ...

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...

The FDA has granted 510(k) clearance to Brain Mets, an AI-based software platform designed to aid in the detection, tracking and treatment planning of brain metastases. The tool, developed by Neosoma, ...

Radiopharm Theranostics RADX shares are down during Tuesday’s trading session following the company’s announcement of ...

A recent Tampa, Fla.-based Moffitt Cancer Center study found that up to 25% of patients with stage 4 breast cancer may develop asymptomatic brain metastasis. The study, published Jan. 24 in ...

A fourth of patients with metastatic breast cancer had asymptomatic brain metastases detected within 6 months after enrolling in a study of MRI-based surveillance. Baseline brain MRI results showed ...

A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests that doctors may need to rethink current screening ...

Decisions around screening for brain metastases in patients with metastatic breast cancer (MBC) can be challenging. To shed some light on the latest screening guidelines and their implications for ...

Preoperative stereotactic radiotherapy (SRT) was just as safe as postoperative SRT for patients with resectable brain metastases. More patients treated with preoperative SRT completed both radiation ...